Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Letter to the Editor

Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer

Author(s): Giandomenico Roviello*, Giuseppe Aprile, Martina Catalano, Monica Ramello, Raffaele Conca and Roberto Petrioli

Volume 23, Issue 15, 2022

Published on: 10 May, 2022

Page: [1788 - 1791] Pages: 4

DOI: 10.2174/1389201023666220307090450

Open Access Journals Promotions 2
« Previous Next »
[1]
Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; Rubinstein, L.; Shankar, L.; Dodd, L.; Kaplan, R.; Lacombe, D.; Verweij, J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer, 2009, 45(2), 228-247.
[http://dx.doi.org/10.1016/j.ejca.2008.10.026] [PMID: 19097774]
[2]
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? Available from: https://europepmc.org/article/med/28602164 (Accessed on Aug 26, 2021).
[3]
FOLFOX vs FOLFIRI as second-line of therapy after progression to gemci | CMAR. Available from: https://www.dovepress.com/folfox-vs-folfiri-as-second-line-of-therapy-after-progression-to-gemci-peer-reviewed-fulltext-article-CMAR (Accessed on Aug 26, 2021).
[4]
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Available from: https://pubmed.ncbi.nlm.nih.gov/26615328/ (Accessed on Aug 26, 2021).
[5]
Oettle, H.; Riess, H.; Stieler, J.M.; Heil, G.; Schwaner, I.; Seraphin, J.; Görner, M.; Mölle, M.; Greten, T.F.; Lakner, V.; Bischoff, S.; Sinn, M.; Dörken, B.; Pelzer, U. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: Outcomes from the CONKO-003 trial. J. Clin. Oncol., 2014, 32(23), 2423-2429.
[http://dx.doi.org/10.1200/JCO.2013.53.6995] [PMID: 24982456]
[6]
Gill, S.; Ko, Y.J.; Cripps, C.; Beaudoin, A.; Dhesy-Thind, S.; Zulfiqar, M.; Zalewski, P.; Do, T.; Cano, P.; Lam, W.Y.H.; Dowden, S.; Grassin, H.; Stewart, J.; Moore, M. PANCREOX: A randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J. Clin. Oncol., 2016, 34(32), 3914-3920.
[http://dx.doi.org/10.1200/JCO.2016.68.5776] [PMID: 27621395]
[7]
Metastatic pancreatic cancer: ASCO guideline update — Johns Hopkins University. Available from: https://jhu.pure.elsevier.com/en/publications/metastatic-pancreatic-cancer-asco-guideline-update (Accessed on Aug 26, 2021).
[8]
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Available from: https://pubmed.ncbi.nlm.nih.gov/31705130/ (Accessed on Aug 26, 2021).
[9]
Catalano, M.; Roviello, G.; Conca, R.; D’Angelo, A.; Palmieri, V.E.; Panella, B.; Petrioli, R.; Ianza, A.; Nobili, S.; Mini, E.; Ramello, M. Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study. Curr. Cancer Drug Targets, 2020, 20(11), 887-895.
[http://dx.doi.org/10.2174/1568009620999200918122426] [PMID: 32957885]

Rights & Permissions Print Cite
Article Metrics
34
3
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy